

Supplemental table 1. Paired sample t-test analyses showing the change from baseline* in Patient Reported Outcome Measures (PROMs) and Best Corrected Visual Acuity (BCVA) measured during 12 months follow-up for all patients and for the subgroups where treatment included better seeing-eye (BSE) and patients for which treatment only included the worse-seeing eye (WSE).

	All patients treated eye			Patients with best seeing eye treated			Patients with worst seeing eye treated		
	0 - 3 m	0 - 6 m	0 - 12 m	0 - 3 m	0 - 6 m	0 - 12 m	0 - 3 m	0 - 6 m	0 - 12 m
BCVA logMAR treated eye	-0.15 (-0.21, -0.10)	-0.17 (-0.23, -0.12)	-0.18 (-0.23, -0.13)	-0.06 (-0.17, 0.05)	-0.10 (-0.20, 0.00)	-0.08 (-0.19, 0.02)	-0.19 (-0.25, -0.12)	-0.20 (-0.26, -0.13)	-0.22 (-0.28, -0.16)
NEI-VFQ-25	2.4 (1.3, 3.5)	2.5 (1.0, 3.9)	1.7 (0.1, 3.3)	5.9 (3.5, 8.3)	5.0 (2.1, 8.0)	4.6 (1.1, 8.1)	1.1 (0.0, 2.3)	1.5 (-0.1, 3.1)	0.6 (-1.1, 2.3)
PASS 5	-0.46 (-0.61, -0.32)	-0.63 (-0.80, -0.46)	-0.49 (-0.65, -0.32)	-0.76 (-1.03, -0.49)	-0.77 (-1.06, -0.47)	-0.62 (-0.93, -0.30)	-0.36 (-0.53, -0.18)	-0.58 (-0.78, -0.38)	-0.44 (-0.64, -0.24)
EQ-5D	-0.02 (-0.05, 0.01)	0.01 (-0.03, 0.04)	0.02 (-0.02, 0.05)	0.01 (-0.06, 0.07)	0.03 (-0.03, 0.10)	0.04 (-0.03, 0.10)	-0.03 (-0.07, 0.01)	-0.01 (-0.05, 0.04)	0.01 (-0.03, 0.05)
DITAMD Management*	NA	0.15 (-0.13, 0.44)	-0.24 (-0.55, 0.07)	NA	0.12 (-0.23, 0.48)	-0.14 (-0.88, 0.59)	NA	0.17 (-0.21, 0.55)	-0.28 (-0.60, 0.04)

*For DiTAMD management, changes are from 3 months and not baseline.